The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study

• Published in: Bone (New York, N.Y.) N.Y.), 2016-11, Vol.92, p.94-99
• Main Authors: Gossiel, F, Hoyle, C, McCloskey, E.V, Naylor, K.E, Walsh, J, Peel, N, Eastell, R
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Aged; Bisphosphonates; Bone Density Conservation Agents - administration & dosage; Bone Remodeling - drug effects; Bone Remodeling - physiology; Diphosphonates - administration & dosage; Female; Flow Cytometry - methods; Humans; Middle Aged; Orthopedics; Osteoclast precursor cells; Osteoclasts; Osteoclasts - drug effects; Osteoclasts - physiology; Osteoporosis; Osteoporosis, Postmenopausal - blood; Osteoporosis, Postmenopausal - drug therapy; Peripheral Blood Stem Cells - drug effects; Peripheral Blood Stem Cells - physiology; Treatment Outcome
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/j.bone.2016.08.010

Abstract Bisphosphonates are used to treat bone disease characterised by increased bone resorption by inhibiting the activity of mature osteoclasts, resulting in decreased bone turnover. Bisphosphonates may also reduce the population of osteoclast precursor cells. Our aims were to investigate the effect of bisphosphonates on i) osteoclast precursor cells and ii) circulating cytokine and cytokine receptor in postmenopausal women with osteoporosis compared with healthy premenopausal women. Participants were 62 postmenopausal women (mean age 66) from a 48-week parallel group trial of bisphosphonates. They received ibandronate 150 mg/month ( n = 22), alendronate 70 mg/week ( n = 19) or risedronate 35 mg/week ( n = 21). Fasting blood was collected at baseline, weeks 1 and 48. At baseline, blood was also collected from 25 healthy premenopausal women (mean age 37) to constitute a control group. Peripheral blood mononuclear cells were extracted and stained for CD14, M-CSFR, CD11b and TNFRII receptors. Flow cytometry was used to identify cells expressing CD14 + and M-CSF + or CD11b + or TNFRII +. RANKL and OPG were measured to evaluate potential mediation of the bisphosphonate effect. After 48 weeks of treatment, there was a decrease in the percentage of cells expressing M-CSFR and CD11b receptors by 53% and 49% respectively ( p < 0.01). Cells expressing M-CSFR and CD11b were decreased with ibandronate and risedronate after 48 weeks to the lower part of the premenopausal reference interval. These effects were not significantly different between each of the treatment groups. There was no significant effect on RANKL and OPG throughout the study period. Bisphosphonates inhibit bone resorption in the short-term by direct action on mature osteoclasts. There is also a later effect mediated in part by a reduction in the population of circulating osteoclast precursors.